Controversial US-backed vaccine trial in African newborns halted
Published . Updated .
Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’ The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It was “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.” Continue reading...
Directly affected
- No company is named in this report.
Indirectly affected
- LMT Lockheed Martin
Defense contractors get more work when conflict spending rises
- RTX RTX
Defense contractors get more work when conflict spending rises
- NOC Northrop Grumman
Defense contractors get more work when conflict spending rises
- GD General Dynamics
Defense contractors get more work when conflict spending rises
- ITA iShares U.S. Aerospace & Defense
A fund of aerospace and defense companies
- BA Boeing
Defense and aerospace orders move with conflict spending
- LHX L3Harris
Defense contractors get more work when conflict spending rises
- HII Huntington Ingalls
Shipyards benefit when naval spending rises
Price reaction, T-5 to T+3
Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’ The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher sai…
Source: The Guardian
How solid the defense case looks
12 out of 100
“Controversial US-backed vaccine trial in African newborns halted” scores 12 out of 100. The score uses 1 sources.